Skip to main content

Edwards Lifesciences Corporation (EW) Stock

Edwards Lifesciences Corporation Stock Details, Movements and Public Alerts

Stock Details

Edwards Lifesciences Corporation (EW), a prominent company in the life sciences sector within the orthopedic, prosthetic & surgical appliances & supplies industry, is based in USA and primarily trades on the NYSE.Currently, the stock is trading at $78.44. Over the past 52 weeks, it has ranged between $58.93 and $89.86. This places the current price at 87.3% of its 52-week high and 33.1% above its 52-week low. Recent trading volume was recorded at 47. The International Securities Identification Number (ISIN) for this stock is US2814771021.

52-Week High

$89.86

-12.71% from high

52-Week Low

$58.93

+33.11% from low

Avg Daily Volume

47

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

32.32

Above market average

Forward P/E

32.05

Earnings expected to grow

PEG Ratio

4.36

Potentially overvalued

Price to Book

4.53

EV/EBITDA

24.07

EPS (TTM)

$2.42

Price to Sales

8.31

Beta

1.12

Similar volatility to market

How is EW valued relative to its earnings and growth?
Edwards Lifesciences Corporation trades at a P/E ratio of 32.32, which is above the market average of approximately 20. This premium valuation suggests investors expect above-average growth or the company has competitive advantages justifying the higher multiple. Looking ahead, the forward P/E of 32.05 is lower than the current P/E, indicating analysts expect earnings to grow over the next year. The PEG ratio of 4.36 indicates a premium valuation even accounting for growth.
What is EW's risk profile compared to the market?
With a beta of 1.12, Edwards Lifesciences Corporation is roughly as volatile as the market, moving in line with broad market trends. This moderate beta suggests the stock offers market-level returns without excessive volatility. The price-to-book ratio of 4.53 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Performance & Growth

Profit Margin

75.70%

Operating Margin

29.00%

Return on Equity

16.50%

Return on Assets

8.42%

Revenue Growth (YoY)

6.20%

Earnings Growth (YoY)

4.20%

How profitable and efficient is EW's business model?
Edwards Lifesciences Corporation achieves a profit margin of 75.70%, meaning it retains $75.70 from every $100 in revenue after all expenses. This is an impressive margin, indicating strong pricing power and efficient cost management that allows the company to generate substantial profits. The operating margin of 29.00% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at 16.50% and ROA at 8.42%, the company generates strong returns on invested capital.
What are EW's recent growth trends?
Edwards Lifesciences Corporation's revenue grew by 6.20% year-over-year, showing steady progress in growing the business. This positive trajectory indicates the company maintains competitive positioning in its markets. Earnings increased by 4.20% year-over-year, reflecting the bottom-line impact of business performance. These growth metrics should be evaluated against ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES industry averages for proper context.

Company Size & Market

Market Cap

$45.88B

Shares Outstanding

586.60M

Book Value/Share

$17.28

Asset Type

Common Stock

What is EW's market capitalization and position?
Edwards Lifesciences Corporation has a market capitalization of $45.88B, classifying it as a large-cap stock ($10B-$200B). Large-caps are typically industry leaders with established business models, offering a balance of stability and growth potential. They often provide dividend income and are core holdings in institutional portfolios. With 586.60M shares outstanding, the company's ownership is relatively concentrated. As a participant in the ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES industry, it competes with other firms in this sector.
How does EW's price compare to its book value?
Edwards Lifesciences Corporation's book value per share is $17.28, while the current stock price is $78.44, resulting in a price-to-book (P/B) ratio of 4.54. This high P/B ratio indicates significant intangible assets, strong brand value, or high growth expectations. Technology and consumer brand companies often trade at elevated P/B ratios due to intellectual property and competitive advantages not reflected on the balance sheet. As a common stock, this represents equity ownership with voting rights.

Analyst Ratings

Analyst Target Price

$81.01

3.28% upside potential

Analyst Recommendations

Strong Buy

5

Buy

10

Hold

17

Sell

1

Strong Sell

0

How reliable are analyst predictions for EW?
33 analysts cover EW with 45% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The mixed views reflect uncertainty about the outlook. The consensus target of $81.01 implies 3.3% upside, but targets are often adjusted to follow price moves rather than predict them.
What is the Wall Street consensus on EW?
Current analyst recommendations:5 Strong Buy, 10 Buy, 17 Hold, 1 Sell, 0The neutral stance suggests uncertainty or fair valuation at current levels.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Jul 1, 2025, 03:31 AM

Technical Indicators

What does EW's RSI value tell investors?
RSI data is not available for this stock.
How should traders interpret EW's MACD and moving average crossovers?
MACD and moving average data are not available for this stock.

No technical indicators available yet.

Active Alerts

No active alerts for this stock.

Be the first to set up an alert for EW and get notified when the price changes.

Stay Ahead of the Market with Edwards Lifesciences Corporation Alerts

Set up price alerts for Edwards Lifesciences Corporation and get notified instantly when the price hits your target. Never miss an important price movement again.